Skip to main content
Top
Published in: Journal of Gastrointestinal Surgery 2/2021

Open Access 01-02-2021 | Hepatocellular Carcinoma | Original Article

Prognostic Nutritional Index and Systemic Immune-Inflammation Index Predict the Prognosis of Patients with HCC

Authors: Dong Wang, Xi Hu, Liang Xiao, Guo Long, Lei Yao, ZhiMing Wang, LeDu Zhou

Published in: Journal of Gastrointestinal Surgery | Issue 2/2021

Login to get access

Abstract

Introduction

Systemic nutrition and inflammation are the critical factors in cancer initiation, evolution, and progression. This study aimed to evaluate the prognostic value of the prognostic nutritional index (PNI) and systemic immune-inflammation index (SII) in hepatocellular carcinoma (HCC) patients who underwent liver resection.

Methods

A total of 202 HCC patients met the criteria and were included in the study. The receiver operating characteristic (ROC) curve was used to calculate the optimal PNI and SII cutoff values. The relationship between PNI/SII and clinicopathologic parameters was analyzed. The effect of PNI and SII on recurrence-free survival (RFS) and overall survival (OS) was investigated by Kaplan-Meier curves and Cox proportional hazards models.

Results

The areas under the ROC curve for PNI and SII were 0.64 and 0.58. The ideal preoperative PNI and SII cutoff values were 50.25 and 461.5, respectively. Multivariate Cox regression analysis identified that the PNI (P = 0.001) and tumor diameter (P = 0.018) were significant prognostic markers for RFS, and that the PNI (P = 0.049), SII (P = 0.039) and tumor diameter (P = 0.001) were significant prognostic markers for OS. The median RFS in the PNI-low and PNI-high groups was 13.5 months and 23 months (P = 0.001), and that in the SII-low and SII-high groups was 18 months and 15 months (P = 0.03), respectively. The median OS in the PNI-low and PNI-high groups was 24 months and 39 months (P = 0.001), and that in the SII-low and SII-high groups was 36 months and 22 months (P = 0.002), respectively.

Conclusion

Interestingly, we found that PNI and SII could be important prognostic parameters for HCC patients who under hepatectomy.
Literature
1.
go back to reference Chen, W., et al., Cancer statistics in China, 2015. CA Cancer J Clin, 2016. 66(2): p. 115–32.CrossRef Chen, W., et al., Cancer statistics in China, 2015. CA Cancer J Clin, 2016. 66(2): p. 115–32.CrossRef
2.
go back to reference Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2019. CA Cancer J Clin, 2019. 69(1): p. 7–34.CrossRef Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2019. CA Cancer J Clin, 2019. 69(1): p. 7–34.CrossRef
3.
go back to reference Llovet, J.M., et al., Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol, 2018. 15(10): p. 599–616.CrossRef Llovet, J.M., et al., Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol, 2018. 15(10): p. 599–616.CrossRef
4.
go back to reference Cadier, B., et al., Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States. Hepatology, 2017. 65(4): p. 1237–1248.CrossRef Cadier, B., et al., Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States. Hepatology, 2017. 65(4): p. 1237–1248.CrossRef
5.
go back to reference Bai, N., et al., circFBLIM1 act as a ceRNA to promote hepatocellular cancer progression by sponging miR-346. J Exp Clin Cancer Res, 2018. 37(1): p. 172.CrossRef Bai, N., et al., circFBLIM1 act as a ceRNA to promote hepatocellular cancer progression by sponging miR-346. J Exp Clin Cancer Res, 2018. 37(1): p. 172.CrossRef
6.
go back to reference Memon, K., et al., Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology, 2011. 141(2): p. 526–35, 535 e1–2.CrossRef Memon, K., et al., Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology, 2011. 141(2): p. 526–35, 535 e1–2.CrossRef
7.
go back to reference El-Khoueiry, A.B., et al., Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet, 2017. 389(10088): p. 2492–2502.CrossRef El-Khoueiry, A.B., et al., Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet, 2017. 389(10088): p. 2492–2502.CrossRef
8.
go back to reference Villanueva, A., et al., Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology, 2011. 140(5): p. 1501–12 e2.CrossRef Villanueva, A., et al., Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology, 2011. 140(5): p. 1501–12 e2.CrossRef
9.
go back to reference Tao, Y.M., et al., BTB/POZ domain-containing protein 7: epithelial-mesenchymal transition promoter and prognostic biomarker of hepatocellular carcinoma. Hepatology, 2013. 57(6): p. 2326–37.CrossRef Tao, Y.M., et al., BTB/POZ domain-containing protein 7: epithelial-mesenchymal transition promoter and prognostic biomarker of hepatocellular carcinoma. Hepatology, 2013. 57(6): p. 2326–37.CrossRef
10.
go back to reference Crusz, S.M. and F.R. Balkwill, Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol, 2015. 12(10): p. 584–96.CrossRef Crusz, S.M. and F.R. Balkwill, Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol, 2015. 12(10): p. 584–96.CrossRef
11.
go back to reference Zitvogel, L., F. Pietrocola, and G. Kroemer, Nutrition, inflammation and cancer. Nat Immunol, 2017. 18(8): p. 843–850.CrossRef Zitvogel, L., F. Pietrocola, and G. Kroemer, Nutrition, inflammation and cancer. Nat Immunol, 2017. 18(8): p. 843–850.CrossRef
12.
go back to reference Morris-Stiff, G., D. Gomez, and K.R. Prasad, C-reactive protein in liver cancer surgery. Eur J Surg Oncol, 2008. 34(7): p. 727–9.CrossRef Morris-Stiff, G., D. Gomez, and K.R. Prasad, C-reactive protein in liver cancer surgery. Eur J Surg Oncol, 2008. 34(7): p. 727–9.CrossRef
13.
go back to reference Diem, S., et al., Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer, 2017. 111: p. 176–181.CrossRef Diem, S., et al., Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer, 2017. 111: p. 176–181.CrossRef
14.
go back to reference Hu, H., et al., Prognostic value of preoperative NLR, dNLR, PLR and CRP in surgical renal cell carcinoma patients. World J Urol, 2017. 35(2): p. 261–270.CrossRef Hu, H., et al., Prognostic value of preoperative NLR, dNLR, PLR and CRP in surgical renal cell carcinoma patients. World J Urol, 2017. 35(2): p. 261–270.CrossRef
15.
go back to reference Ying, H.Q., et al., The prognostic value of preoperative NLR, d-NLR, PLR and LMR for predicting clinical outcome in surgical colorectal cancer patients. Med Oncol, 2014. 31(12): p. 305.CrossRef Ying, H.Q., et al., The prognostic value of preoperative NLR, d-NLR, PLR and LMR for predicting clinical outcome in surgical colorectal cancer patients. Med Oncol, 2014. 31(12): p. 305.CrossRef
16.
go back to reference Chen, J.H., et al., Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol, 2017. 23(34): p. 6261–6272.CrossRef Chen, J.H., et al., Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol, 2017. 23(34): p. 6261–6272.CrossRef
17.
go back to reference Diao, P., et al., Preoperative systemic immune-inflammation index predicts prognosis of patients with oral squamous cell carcinoma after curative resection. J Transl Med, 2018. 16(1): p. 365.CrossRef Diao, P., et al., Preoperative systemic immune-inflammation index predicts prognosis of patients with oral squamous cell carcinoma after curative resection. J Transl Med, 2018. 16(1): p. 365.CrossRef
18.
go back to reference Jomrich, G., et al., Systemic Immune-Inflammation Index (SII) Predicts Poor Survival in Pancreatic Cancer Patients Undergoing Resection. J Gastrointest Surg, 2019. Jomrich, G., et al., Systemic Immune-Inflammation Index (SII) Predicts Poor Survival in Pancreatic Cancer Patients Undergoing Resection. J Gastrointest Surg, 2019.
19.
go back to reference Tokunaga, R., et al., Prognostic Nutritional Index Predicts Severe Complications, Recurrence, and Poor Prognosis in Patients With Colorectal Cancer Undergoing Primary Tumor Resection. Dis Colon Rectum, 2015. 58(11): p. 1048–57.CrossRef Tokunaga, R., et al., Prognostic Nutritional Index Predicts Severe Complications, Recurrence, and Poor Prognosis in Patients With Colorectal Cancer Undergoing Primary Tumor Resection. Dis Colon Rectum, 2015. 58(11): p. 1048–57.CrossRef
20.
go back to reference Okadome, K., et al., Prognostic Nutritional Index, Tumor-infiltrating Lymphocytes, and Prognosis in Patients with Esophageal Cancer. Ann Surg, 2018. Okadome, K., et al., Prognostic Nutritional Index, Tumor-infiltrating Lymphocytes, and Prognosis in Patients with Esophageal Cancer. Ann Surg, 2018.
21.
go back to reference Buzby, G.P., et al., Prognostic nutritional index in gastrointestinal surgery. Am J Surg, 1980. 139(1): p. 160–7.CrossRef Buzby, G.P., et al., Prognostic nutritional index in gastrointestinal surgery. Am J Surg, 1980. 139(1): p. 160–7.CrossRef
22.
go back to reference Zhang, H., et al., The predictive value of a preoperative systemic immune-inflammation index and prognostic nutritional index in patients with esophageal squamous cell carcinoma. J Cell Physiol, 2019. 234(2): p. 1794–1802.CrossRef Zhang, H., et al., The predictive value of a preoperative systemic immune-inflammation index and prognostic nutritional index in patients with esophageal squamous cell carcinoma. J Cell Physiol, 2019. 234(2): p. 1794–1802.CrossRef
23.
go back to reference Huang, X., et al., Prognostic value of prognostic nutritional index and systemic immune-inflammation index in patients with osteosarcoma. J Cell Physiol, 2019. 234(10): p. 18408–18414.CrossRef Huang, X., et al., Prognostic value of prognostic nutritional index and systemic immune-inflammation index in patients with osteosarcoma. J Cell Physiol, 2019. 234(10): p. 18408–18414.CrossRef
24.
go back to reference Geng, Y., et al., Prognostic nutritional index predicts survival and correlates with systemic inflammatory response in advanced pancreatic cancer. Eur J Surg Oncol, 2015. 41(11): p. 1508–14.CrossRef Geng, Y., et al., Prognostic nutritional index predicts survival and correlates with systemic inflammatory response in advanced pancreatic cancer. Eur J Surg Oncol, 2015. 41(11): p. 1508–14.CrossRef
25.
go back to reference Ostroumov, D., et al., CD4 and CD8 T lymphocyte interplay in controlling tumor growth. Cell Mol Life Sci, 2018. 75(4): p. 689–713.CrossRef Ostroumov, D., et al., CD4 and CD8 T lymphocyte interplay in controlling tumor growth. Cell Mol Life Sci, 2018. 75(4): p. 689–713.CrossRef
26.
go back to reference Menter, D.G., et al., Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Rev, 2014. 33(1): p. 231–69.CrossRef Menter, D.G., et al., Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Rev, 2014. 33(1): p. 231–69.CrossRef
27.
go back to reference Wojtukiewicz, M.Z., et al., Platelets and cancer angiogenesis nexus. Cancer Metastasis Rev, 2017. 36(2): p. 249–262.CrossRef Wojtukiewicz, M.Z., et al., Platelets and cancer angiogenesis nexus. Cancer Metastasis Rev, 2017. 36(2): p. 249–262.CrossRef
28.
go back to reference Ocana, A., et al., Neutrophils in cancer: prognostic role and therapeutic strategies. Mol Cancer, 2017. 16(1): p. 137.CrossRef Ocana, A., et al., Neutrophils in cancer: prognostic role and therapeutic strategies. Mol Cancer, 2017. 16(1): p. 137.CrossRef
29.
go back to reference Wang, D., et al., Preoperative inflammatory markers of NLR and PLR as indicators of poor prognosis in resectable HCC. PeerJ, 2019. 7: p. e7132.CrossRef Wang, D., et al., Preoperative inflammatory markers of NLR and PLR as indicators of poor prognosis in resectable HCC. PeerJ, 2019. 7: p. e7132.CrossRef
Metadata
Title
Prognostic Nutritional Index and Systemic Immune-Inflammation Index Predict the Prognosis of Patients with HCC
Authors
Dong Wang
Xi Hu
Liang Xiao
Guo Long
Lei Yao
ZhiMing Wang
LeDu Zhou
Publication date
01-02-2021
Publisher
Springer US
Published in
Journal of Gastrointestinal Surgery / Issue 2/2021
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-019-04492-7

Other articles of this Issue 2/2021

Journal of Gastrointestinal Surgery 2/2021 Go to the issue